These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 37637082)

  • 1. From oncolytic peptides to oncolytic polymers: A new paradigm for oncotherapy.
    Liu H; Shen W; Liu W; Yang Z; Yin D; Xiao C
    Bioact Mater; 2024 Jan; 31():206-230. PubMed ID: 37637082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic.
    Zou H; Mou XZ; Zhu B
    Glob Chall; 2023 Jan; 7(1):2200094. PubMed ID: 36618103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of oncolytic viruses for cancer therapy.
    Abd-Aziz N; Poh CL
    Transl Res; 2021 Nov; 237():98-123. PubMed ID: 33905949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
    Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
    Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer.
    Lu L; Zhang H; Zhou Y; Lin J; Gao W; Yang T; Jin J; Zhang L; Nagle DG; Zhang W; Wu Y; Chen H; Luan X
    Theranostics; 2022; 12(7):3456-3473. PubMed ID: 35547769
    [No Abstract]   [Full Text] [Related]  

  • 6. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
    Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
    J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic Adenovirus: Prospects for Cancer Immunotherapy.
    Zhao Y; Liu Z; Li L; Wu J; Zhang H; Zhang H; Lei T; Xu B
    Front Microbiol; 2021; 12():707290. PubMed ID: 34367111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
    Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
    Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic immunotherapy: multiple mechanisms of oncolytic peptides to confer anticancer immunity.
    Tang T; Huang X; Zhang G; Liang T
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abscopal effects observed in cancer radiation therapy and oncolytic virotherapy: an overview.
    Romano G; Marino IR
    Drugs Today (Barc); 2019 Feb; 55(2):117-130. PubMed ID: 30816886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them.
    Hu PY; Fan XM; Zhang YN; Wang SB; Wan WJ; Pan HY; Mou XZ
    Appl Microbiol Biotechnol; 2020 Oct; 104(19):8231-8242. PubMed ID: 32816087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy.
    Ban W; Guan J; Huang H; He Z; Sun M; Liu F; Sun J
    Nano Res; 2022; 15(5):4137-4153. PubMed ID: 35194488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual tumor targeting with pH-sensitive and bioreducible polymer-complexed oncolytic adenovirus.
    Moon CY; Choi JW; Kasala D; Jung SJ; Kim SW; Yun CO
    Biomaterials; 2015 Feb; 41():53-68. PubMed ID: 25522965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic viruses: do they have a role in anti-cancer therapy?
    Prestwich RJ; Errington F; Harrington KJ; Pandha HS; Selby P; Melcher A
    Clin Med Oncol; 2008; 2():83-96. PubMed ID: 21892269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nano based-oncolytic viruses for cancer therapy.
    Ajam-Hosseini M; Akhoondi F; Doroudian M
    Crit Rev Oncol Hematol; 2023 May; 185():103980. PubMed ID: 37001838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards targeted cancer therapy: Aptamer or oncolytic virus?
    Tan KX; Danquah MK; Sidhu A; Ongkudon CM; Lau SY
    Eur J Pharm Sci; 2017 Jan; 96():8-19. PubMed ID: 27593990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic virotherapy: Challenges and solutions.
    Goradel NH; Baker AT; Arashkia A; Ebrahimi N; Ghorghanlu S; Negahdari B
    Curr Probl Cancer; 2021 Feb; 45(1):100639. PubMed ID: 32828575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines.
    Feola S; Chiaro J; Martins B; Russo S; Fusciello M; Ylösmäki E; Bonini C; Ruggiero E; Hamdan F; Feodoroff M; Antignani G; Viitala T; Pesonen S; Grönholm M; Branca RMM; Lehtiö J; Cerullo V
    Elife; 2022 Mar; 11():. PubMed ID: 35314027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic Adenoviruses Armed with Co-Stimulatory Molecules for Cancer Treatment.
    Gryciuk A; Rogalska M; Baran J; Kuryk L; Staniszewska M
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.